Results 121 to 130 of about 148,412 (201)

Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. [PDF]

Curr Oncol Rep
Najdawi F, Sayyid RK, Ahlering T, Lee DI, Dobbs RW, Shahait M.   +5 more
europepmc   +1 more source

Challenges of Prostatic Tuberculosis: When Infection and Neoplasia Coexist. [PDF]

Cureus
Sandoval Enriquez KG, Parra Herrera JL, Carrillo Hernández M, Angeles-Castellanos M, Martínez Aguilar JA.   +4 more
europepmc   +1 more source

A comparative Study of Aptasensor Vs Immunosensor for Label-Free PSA Cancer Detection on GQDs-AuNRs Modified Screen-Printed Electrodes. [PDF]

Sci Rep, 2018
Srivastava M, Nirala NR, Srivastava SK, Prakash R.   +3 more
europepmc   +1 more source

Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. [PDF]

Front Oncol
Huang H, Hu J, Lan X, Li H, Chen J.
europepmc   +1 more source

Increased synovial and entheseal fibroblast activation detected by ⁶⁸Ga-FAPI-PET/CT is associated with the development of psoriatic arthritis in psoriasis patients with arthralgia. [PDF]

RMD Open
Corte G, Atzinger A, Noversa de Sousa R, Mutlu MY, Temiz A, Bayat S, Raimondo MG, Ramming A, Sticherling M, Schmidkonz C, Kuwert T, Schett G, Tascilar K, Fagni F.   +13 more
europepmc   +1 more source

Long-term outcomes of external beam radiotherapy combined with high-dose-rate brachytherapy boost in intermediate- and high-risk prostate cancer. [PDF]

Front Oncol
Tas KT, Spartmann T, Smalec E, Lishewski P, Sheikhzadeh FF, Boettcher M, Zink K, Fragkandrea-Nixon I, Huber J, Gawish A, Adeberg S.   +10 more
europepmc   +1 more source

Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan. [PDF]

Psoriasis (Auckl)
Xu Y, Li T, Chang CL, Zhang Y, Masuda J, Wu GH, Wahking B, Imafuku S, Qiu H.   +8 more
europepmc   +1 more source

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide. [PDF]

J Clin Med
Ozkerim U, Kinikoglu O, Isik D, Altintas YE, Ay Ersoy S, Surmeli H, Odabas H, Basoglu T, Turan N.   +8 more
europepmc   +1 more source

Prognostic value of baseline circulating tumor DNA levels in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Liao Y, Lin Y, Luo B, Shen J.
europepmc   +1 more source

Effect of apalutamide dosage on the incidence of cutaneous adverse events and prostate-specific antigen reduction in patients with prostate cancer. [PDF]

Oncol Lett
Matsuyama T, Kimura M, Go M, Yamada S, Nishimura M, Murase H, Matsuyama R, Usami E.   +7 more
europepmc   +1 more source